Omeros Corporation (OMER)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Omeros Corporation (OMER) Earnings: Report Dates and Results
Omeros (OMER) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Omeros reported EPS of $0.02, above the -$0.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OMER has an expected report date of Mar 29, 2027.
OMER Earnings Call
The latest OMER earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, OMER beat 21, missed 18 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 459.65% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $0.02 | -$0.27 | -$0.39 - -$0.27 | +107.41% | Beat | N/A | 2 | 1 up, 0 down | Aug 13, 2026 | $28.53M |
| Mar 31, 2026 | $0.57 | -$0.39 | -$0.40 - -$0.38 | +246.15% | Beat | N/A | 3 | 1 up, 0 down | May 13, 2026 | $9.89M |
| Dec 31, 2025 | -$0.55 | -$0.52 | -$0.62 - $2.24 | -5.04% | Miss | N/A | 3 | 1 up, 0 down | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$0.32 | -$0.48 | -$0.58 - -$0.37 | +33.33% | Beat | N/A | 4 | 1 up, 3 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$0.53 | -$0.55 | -$0.74 - -$0.44 | +3.64% | Beat | N/A | 4 | 0 up, 1 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.65 | -$0.58 | -$0.74 - -$0.53 | -12.07% | Miss | N/A | 3 | 0 up, 0 down | May 15, 2025 | N/A |
| Dec 31, 2024 | -$0.55 | -$0.71 | -$1.07 - -$0.48 | +22.54% | Beat | N/A | 3 | 1 up, 1 down | Mar 31, 2025 | N/A |
| Sep 30, 2024 | -$0.64 | -$0.77 | -$0.77 - -$0.64 | +16.88% | Beat | N/A | 2 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$1.12 | -$1.01 | -$1.51 - -$0.94 | -10.89% | Miss | N/A | 3 | 0 up, 1 down | Aug 7, 2024 | N/A |
| Mar 31, 2024 | -$0.75 | -$0.63 | N/A | -19.05% | Miss | N/A | 3 | 0 up, 0 down | Apr 1, 2024 | N/A |
| Dec 31, 2023 | -$0.15 | -$0.55 | -$0.65 - -$0.46 | +72.73% | Beat | -107.3% | 2 | 0 up, 0 down | Mar 26, 2024 | N/A |
| Sep 30, 2023 | -$0.82 | -$0.66 | -$0.68 - -$0.56 | -24.24% | Miss | N/A | 3 | 1 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.70 | -$0.53 | N/A | -32.08% | Miss | N/A | 3 | 0 up, 0 down | Aug 9, 2023 | N/A |
| Mar 31, 2023 | -$0.63 | -$0.57 | -$0.72 - -$0.41 | -10.53% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | $2.05 | -$0.57 | -$0.64 - -$0.47 | +459.65% | Beat | N/A | 5 | 1 up, 0 down | Mar 13, 2023 | N/A |
| Sep 30, 2022 | -$0.87 | -$0.58 | N/A | -50.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 9, 2022 | N/A |
| Jun 30, 2022 | -$0.66 | -$0.66 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$0.53 | -$0.69 | -$0.78 - -$0.61 | +23.19% | Beat | N/A | 3 | 0 up, 1 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.37 | -$0.36 | -$0.48 - -$0.30 | -2.78% | Miss | N/A | 5 | 0 up, 0 down | Mar 1, 2022 | N/A |
| Sep 30, 2021 | -$0.36 | -$0.47 | -$0.51 - -$0.45 | +23.40% | Beat | N/A | 7 | 1 up, 0 down | Nov 9, 2021 | N/A |
| Jun 30, 2021 | -$0.46 | -$0.55 | -$0.75 - -$0.44 | +16.36% | Beat | N/A | 8 | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$0.57 | -$0.51 | -$0.80 - -$0.37 | -11.76% | Miss | N/A | 6 | N/A | May 10, 2021 | N/A |
| Dec 31, 2020 | -$0.60 | -$0.69 | -$0.83 - -$0.44 | +13.04% | Beat | N/A | 7 | N/A | Mar 1, 2021 | N/A |
| Sep 30, 2020 | -$0.34 | -$0.49 | -$1.31 - -$0.37 | +30.61% | Beat | N/A | 7 | N/A | Nov 9, 2020 | $26.11M |
| Jun 30, 2020 | -$0.61 | -$0.59 | -$0.93 - -$0.38 | -3.39% | Miss | N/A | 6 | N/A | Aug 10, 2020 | $13.53M |
| Mar 31, 2020 | -$0.53 | -$0.34 | -$0.44 - -$0.23 | -55.88% | Miss | N/A | 5 | N/A | May 11, 2020 | $23.54M |
| Dec 31, 2019 | -$0.58 | -$0.50 | -$0.98 - -$0.24 | -16.00% | Miss | N/A | 6 | N/A | Mar 2, 2020 | N/A |
| Sep 30, 2019 | -$0.33 | -$0.41 | -$0.57 - -$0.26 | +19.51% | Beat | N/A | 6 | N/A | Nov 12, 2019 | $29.86M |
| Jun 30, 2019 | -$0.29 | -$0.44 | -$0.58 - -$0.37 | +34.09% | Beat | N/A | 6 | N/A | Aug 8, 2019 | $26.75M |
| Mar 31, 2019 | -$0.50 | -$0.47 | N/A | -6.38% | Miss | N/A | 4 | N/A | May 9, 2019 | $21.78M |
| Dec 31, 2018 | -$0.21 | -$0.81 | -$1.10 - -$0.60 | +74.07% | Beat | N/A | 5 | N/A | Mar 1, 2019 | $22.02M |
| Sep 30, 2018 | -$0.81 | -$0.71 | -$1.03 - -$0.68 | -14.08% | Miss | N/A | 5 | N/A | Nov 8, 2018 | $4.61M |
| Jun 30, 2018 | -$0.70 | -$0.62 | -$0.90 - -$0.52 | -12.90% | Miss | N/A | 6 | N/A | Aug 9, 2018 | $1.66M |
| Mar 31, 2018 | -$0.62 | -$0.59 | -$0.64 - -$0.50 | -5.08% | Miss | N/A | 4 | N/A | May 10, 2018 | $1.59M |
| Dec 31, 2017 | -$0.34 | -$0.17 | -$0.30 - -$0.06 | -100.00% | Miss | N/A | 5 | N/A | Mar 1, 2018 | $13.76M |
| Sep 30, 2017 | -$0.16 | -$0.34 | -$0.42 - -$0.26 | +52.94% | Beat | N/A | 5 | N/A | Nov 9, 2017 | $21.66M |
| Jun 30, 2017 | -$0.33 | -$0.37 | -$0.50 - -$0.29 | +10.81% | Beat | N/A | 6 | N/A | Aug 8, 2017 | $17.15M |
| Mar 31, 2017 | -$0.34 | -$0.35 | N/A | +2.86% | Beat | N/A | N/A | N/A | May 10, 2017 | $12.26M |
| Dec 31, 2016 | -$0.45 | -$0.56 | N/A | +19.64% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $12.90M |
| Sep 30, 2016 | -$0.34 | -$0.36 | N/A | +5.56% | Beat | N/A | N/A | N/A | Nov 9, 2016 | $11.29M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.05, after -$3.06 the year before. It was -$1.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.05 | N/A |
| Dec 31, 2024 | -$3.06 | N/A |
| Dec 31, 2023 | -$2.30 | N/A |
| Dec 31, 2022 | -$0.01 | N/A |
| Dec 31, 2021 | -$1.76 | N/A |
| Dec 31, 2020 | -$2.08 | N/A |
| Dec 31, 2019 | -$1.70 | N/A |
| Dec 31, 2018 | -$2.34 | N/A |
| Dec 31, 2017 | -$1.17 | N/A |
| Dec 31, 2016 | -$1.65 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,700 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,732 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,860 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,519 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,199 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,046 | 9 | |
| 2025Q1 | Mar 31, 2025 | 3,978 | 6 | |
| 2024Q4 | Dec 31, 2024 | 7,074 | 11 | |
| 2024Q3 | Sep 30, 2024 | 5,331 | 9 |
2026Q2 Earnings Call
Opening remarks
Jennifer Williams Investor Relations Please go ahead.
Gregory A. Demopulos Chairman and CEO Thank you, and good afternoon, everyone. Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the risk factors in our quarterly report on Form 10-Q filed today with the SEC as well as our most recent annual report on Form 10-K. Today's call also will include certain non-GAAP financial measures. A reconciliation of these measures to the corresponding GAAP measures is included in Omeros' earnings release issued earlier today available on the Investor Relations page of our website and furnished with the form 8-K we filed today with the SEC. With that, I will turn the call over to Dr. Gregory Demopulos, Chairman and CEO of Omeros. Thank you, Jennifer, and good afternoon, everyone. Joining me today are David J. Borges, our chief accounting officer, Dr. Kathy Melfi, our chief regulatory officer, Dr. Steve Whitaker, vice president of clinical, and David W. Ghesquiere, our chief commercial officer. Promoted from within the company, David was recently appointed as our chief commercial officer, and let me tell you a bit more about him. David joined Omeros six years ago as our vice president of sales and market development, bringing more than 25 years of industry experience, including sales and marketing leadership roles at Amgen, Spectrum Pharmaceuticals, and Jazz Pharmaceuticals, where he led the global launch of defibrotide. David largely built our commercial team and was instrumental in designing and executing the Yartemlia launch. I have long believed that his background, capabilities, and achievements are ideally suited to Omeros' current and future objectives. Under his leadership, our commercial team is driving Yartemlia toward becoming the standard of care for TA-TMA, and preparing for its expansion into a broad range of MASP-2-driven indications. Beyond that, David's track record of driving growth across oncology, rare disease, and specialty biopharma products will serve Omeros well. Before I turn to the financial details, let me highlight three points. First, Yartemlia generated $32.2 million in gross sales in its first full quarter on the market. Second, operations generated $4.1 million of positive cash flow during the quarter. And third, we meaningfully strengthened our capital structure through our share and note repurchases. So I will now begin with an overview of our second quarter operations and financial results, followed by program updates. David will then review the financials in more detail, after which we will open the call for questions.
Frequently Asked Questions About OMER
When is Omeros's next earnings date?
Omeros's next earnings report is expected for Mar 29, 2027.
Did OMER beat earnings estimates last quarter?
Yes. Omeros reported EPS of $0.02 for the quarter ended Jun 30, 2026, above the -$0.27 estimate, a 107.41% surprise.
What EPS do analysts expect from OMER next quarter?
The consensus EPS estimate for Omeros for the quarter ending Dec 31, 2026 is $0.07 from 5 analysts, with estimates from -$0.02 to $0.14.
How often does OMER beat earnings estimates?
Omeros beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +51.61%.
OMER pages: Overview, Earnings, Forecast, Financials, Competitors